Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1
CEND-1 (iRGD) is a bifunctional cyclic peptide that can modulate the solid tumour microenvironment, enhancing the delivery and therapeutic index of co-administered anti-cancer agents. This study explored CEND-1’s pharmacokinetic (PK) properties pre-clinically and clinically, and assessed CEND-1 dist...
Main Authors: | Harri A. Järveläinen, Christian Schmithals, Maike von Harten, Bianca Kakoschky, Thomas J. Vogl, Stephen Harris, Claire Henson, Gemma Bullen-Clerkson, Albrecht Piiper |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/6/5700 |
Similar Items
-
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
by: Sujin Kang, et al.
Published: (2020-08-01) -
Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01) -
Planejamento de atividades anti-tuberculose pelo método CENDES/OPS Planning of antituberculosis activities by the "CENDES/ PAHO" method
by: Gilberto Ribeiro Arantes
Published: (1976-03-01) -
iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma
by: Yanbing Dong, et al.
Published: (2023-03-01) -
Tumor Microenvironment-Responsive Polymeric iRGD and Doxorubicin Conjugates Reduce Spontaneous Lung Metastasis in an Orthotopic Breast Cancer Model
by: Zheng-Hong Peng, et al.
Published: (2022-08-01)